## **AMENDMENTS TO THE CLAIMS**

Docket No.: 64921(45579)

Claim 1. (currently amended) A compound of formula (I)

$$R_{1}$$
 $R_{2}$ 
 $R_{3}$ 
 $R_{3}$ 

or a pharmaceutical acceptable salt or ester thereof,

wherein

X is -CONHOH, -COOH,-OH, or-SH;

 $R_1$  is selected from the group consisting of  $C_{1-6}$  alkyl,  $C_{3-10}$  cycloalkyl,  $C_{1-6}$  alkylmercapto,  $C_{1-6}$  alkylthio- $C_{1-6}$  alkyl,  $C_{1-6}$  alkylhydroxy,  $C_{1-6}$  alkylcarboxy,  $C_{1-6}$  alkylamide,  $C_{1-6}$  alkylamino, alkylamino- $C_{1-6}$  alkyl, dialkylamino- $C_{1-6}$  alkyl,  $C_{1-6}$  alkylamidine,  $C_{1-6}$  alkylguanidine, an unsubstituted or substituted aryl group, an unsubstituted or substituted  $C_{1-6}$  alkylaryl group, an unsubstituted or substituted  $C_{1-6}$  alkylaryl group, an unsubstituted or substituted  $C_{1-6}$  alkylheteroaryl group and a side <u>chain</u> ehains-of a natural alpha amino acid;

with the proviso that R<sub>1</sub> cannot be hydrogen or tert-butyl;

 $R_2$  is selected from the group consisting of  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{3-10}$  cycloalkyl,  $C_{1-6}$  alkyl- $C_{3-10}$  cycloalkyl,  $C_{3-7}$  heterocycloalkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylamino,  $C_{1-6}$  alkylmercapto,  $C_{1-6}$  alkylhydroxy, thio  $C_{1-6}$  alkyl, alkylamino- $C_{1-6}$  alkyl, dialkylamino- $C_{1-6}$  alkyl, an unsubstituted or substituted aryl group, an unsubstituted or substituted  $C_{1-6}$  alkylaryl group and an unsubstituted or substituted  $C_{1-6}$  alkylheteroaryl group;

R<sub>3</sub> is-NHCH (R<sub>4</sub>) COR<sub>5</sub>,-NR<sub>6</sub>R<sub>7</sub>,-NHR<sub>7</sub> or-OR<sub>7</sub>;

R<sub>4</sub> is selected from the group consisting of hydrogen and a side chain of a natural alpha amino acid;

R<sub>5</sub> is amino, hydroxy, C<sub>1-6</sub> alkoxy or -NH-C<sub>1-6</sub> alkyl;

 $R_6$  and  $R_7$  are identical or different and are independently of each other selected from the group consisting of  $C_{3-7}$  heterocycloalkyl, an unsubstituted or substituted  $C_{1-6}$  alkyl-  $C_{3-7}$  heterocycloalkyl group, an unsubstituted or substituted aryl group, an unsubstituted or substituted or substituted  $C_{1-6}$  alkylaryl group and an unsubstituted or substituted  $C_{1-6}$  alkylaryl group and an unsubstituted or substituted  $C_{1-6}$  alkylheteroaryl group;

Docket No.: 64921(45579)

wherein a substituted group is substituted with one, two or three substituents independently selected from halogen, hydroxy, amino, mercapto, nitro, cyano, trifluoromethyl,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, thio $C_{1-6}$  alkyl,  $C_{1-6}$  alkylamino- $C_{1-6}$ 

- Claim 2. (original) A compound according to claim 1, wherein X is -CONHOH.
- Claim 3. (original) A compound according to claim 1, wherein X is -COOH.
- Claim 4. (original) A compound according to claim 1, wherein X is selected among -OH and -SH.
- Claim 5. (currently amended) A compound according to <u>claim 1 any of</u> the preceding claims, wherein R<sub>1</sub> is a side chain of a natural alpha amino acid <u>selected</u> from the group consisting of such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamin, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine.

Page 4

Claim 6. (currently amended) A compound according to claim 1-any-of elaims 1-4, wherein  $R_1$  is  $C_{1-6}$  alkyl,  $C_{3-10}$  cycloalkyl,  $C_{1-6}$  alkylmercapto,  $C_{1-6}$  alkylthio- $C_{1-6}$  alkyl,  $C_{1-6}$  alkylhydroxy,  $C_{1-6}$  alkylcarboxy,  $C_{1-6}$  alkylamide,  $C_{1-6}$  alkylamino, alkylamino- $C_{1-6}$  alkyl, dialkylamino- $C_{1-6}$  alkyl,  $C_{1-6}$  alkylamidine,  $C_{1-6}$  alkylguanidine, an unsubstituted or substituted aryl group, an unsubstituted or substituted or substit

Docket No.: 64921(45579)

Claim 7. (currently amended) A compound according to <u>claim 1 any of claims 1-4</u>, wherein R<sub>1</sub> is ethyl, isobutyl, 2- (methylsulfanyl) ethyl, 4-aminobutyl, benzyl, 4-hydroxybenzyl, 2-phenylethyl and naphth-1-yl-methyl.

Claim 8. (currently amended) A compound according to claim 1-any-of the preceding claims, wherein  $R_2$  is selected from the group consisting of  $C_{1-6}$  alkyl,  $C_{3-10}$  cycloalkyl,  $C_{1-6}$  alkyl- $C_{3-10}$  cycloalkyl,  $C_{1-6}$  alkylamino,  $C_{1-6}$  alkylhydroxy, an unsubstituted or substituted  $C_{1-6}$  alkylaryl group and an unsubstituted or substituted  $C_{1-6}$  alkylheteroaryl group, wherein a substituted group is substituted with one, two or three substituents independently selected from halogen, hydroxy, amino, mercapto, nitro, cyano, trifluoromethyl,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, and thio $C_{1-6}$  alkyl.

Claim 9. (currently amended) A compound according to claim 1 any of elaims 1-7, wherein R<sub>2</sub> is selected from the group consisting of ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, aminopropyl, aminobutyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, an phenyl, fluorosubstituted phenyl, chlorosubstituted phenyl, thiophenylethyl and furanylmethyl.

Claim 10. (original) A compound according to claim 9, wherein  $R_2$  is butyl, cyclopropyl, cyclohexylmethyl, 2-aminoethyl, 2-hydroxyethyl, benzyl, 2-chlorobenzyl, 4- chlorobenzyl, 2, 6-difluorobenzyl, 2-thiophen-2-ylethyl or furan-2-ylmethyl.

Docket No.: 64921(45579)

- Claim 11. (currently amended) A compound according to <u>claim 1 any of</u> the <u>preceding claims</u>, wherein R<sub>3</sub> is -NHCH(R<sub>4</sub>)COR<sub>5</sub>.
- Claim 12. (currently amended) A compound according to claim 1 any of claims 1-10, wherein R<sub>3</sub> is -NHR<sub>7</sub> or -NR<sub>6</sub>R<sub>7</sub>.
- Claim 13. (currently amended) A compound according to claim 1 any of claims 1–10, wherein R<sub>3</sub> is -OR<sub>7</sub>.
- Claim 14. (currently amended) A compound according to <u>claim 1-any of claims 1-11</u>, wherein R<sub>4</sub> is a side chain of a natural alpha amino acid <u>selected from the group consisting of such as alanine</u>, arginine, asparagine, aspartic acid, cysteine, glutamin, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine.
- Claim 15. (currently amended) A compound according to <u>claim 1</u>-any-of claims 1-11, 14, wherein R<sub>4</sub> is hydrogen.
- Claim 16. (currently amended) A compound according to <u>claim 1 any of claims 1-11, 14-15</u>, wherein  $R_5$  is  $C_{1-6}$  alkoxy.

Docket No.: 64921(45579)

- Claim 17. (currently amended) A compound according to <u>claim 1-any of</u> claims 1-11, 14-16, wherein R<sub>5</sub> is methoxy, ethoxy, propoxy or butoxy.
- Claim 18. (currently amended) A compound according to <u>claim 1-any-of</u> claims 1-10, 12-13, wherein  $R_6$  or  $R_7$  is  $C_{3-7}$  heterocycloalkyl or an unsubstituted or substituted  $C_{1-6}$  alkyl- $C_{3-7}$  heterocycloalkyl group.
- Claim 19. (currently amended) A compound according to <u>claim 1</u>-any of claims 1-10, 12-13, wherein  $R_6$  or  $R_7$  is an unsubstituted or substituted aryl group, an unsubstituted or substituted  $C_{1-6}$  alkylaryl group or an unsubstituted or substituted  $C_{1-6}$  alkylheteroaryl group.
- Claim 20. (original) A compound according to claim 1 selected from the group consisting of
- ({1-cyclopropyl-2-[1- (3-mercapto-propionylamino)-propyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1- (4-chloro-benzyl)-2-[1- (3-mercapto-propionylamino)-2-phenyl-ethyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- N- {1- [1-benzyl-5-(methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-3-methylsulfanyl-propyl}-succinamic acid,
- N-{1-[1-butyl-5-(methoxycarbonylmethyl-carbamoyl)-1H-benzoimidazol-2-yl]-2-phenylethyl}-succinamic acid,
- N-{1- [1-furan-2-ylmethyl-5-(methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-2-phenyl-ethyl}-succinamic acid,
- N-{1- [1- (4-chloro-benzyl)-5-(methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-2-phenyl-ethyl}-succinamic acid,
- N-{1- [1-cyclopropyl-5-(methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-3-phenyl-propyl}-succinamic acid,

- N-{1- [1-cyclohexylmethyl-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-3-phenyl-propyl}-succinamic acid,
- N-{1- [1- (2-chloro-benzyl)-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2- yl]-3-phenyl-propyl}-succinamic acid,
- N-{1- [1-cyclopropyl-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-propyl}-succinamic acid,
- N-{1- [1-furan-2-ylmethyl-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-propyl}-succinamic acid,
- N-{1-[1-benzyl-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-propyl}-succinamic acid,
- N-{1-[1-cyclopropyl-5- (methoxycarbonylmethyl-carbamoyl)-l H-benzoimidazol-2-yi]-3-methyl-butyl}-succinamic acid,
- N-{1-[1-butyl-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-3-methyl-butyl}-succinamic acid,
- N-{1-[1-benzyl-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-3-methyl-butyl}-succinamic acid,
- N-{1-[1-cyclopropyl-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-3-methylsulfanyl-propyl}-succinamic acid,
- N-{1-[5-(methoxycarbonylmethyl-carbamoyl)-1-(2-thiophen-2-yl-ethyl)-1 H-benzoimidazol-2-yl]-2-naphthalen-1-yl-ethyl}-succinamic acid,
- N-{1- [1-butyl-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimid zol-2-yl]-2-naphthalen-1-yl-ethyl}-succinamic acid,
- ({2-[5-amino-1-(3-mercapto-propionylamino)-pentyl]-1-cyclohexylmethyl-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-cyclopropyl-2-[2-(4-hydroxy-phenyl)-1- (3-mercapto-propionylamino)-ethyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-cyclohexylmethyl-2-[2-(4-hydroxy-phenyl)-1- (3-mercapto-propionylamino)-ethyl]-1 H- benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,

({1-(2-hydroxy-ethyl)-2-[1-(3-mercapto-propionylamino)-2-phenyl-ethyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,

N-{5-amino-1- [1-cyclopropyl-5-(methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol- 2-yl]-pentyl}-succinamic acid,

N-{5-amino-1-[1-cyclohexylmethyl-5-(methoxycarbonylmethyl-carbamoyl)-1H-benzoimidazol-2-yl]-pentyl}-succinamic acid,

N-[1-[1-cyclopropyl-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-2- (4-hydroxyphenyl)-ethyl]-succinamic acid,

N-[1-[1-cyclohexylmethyl-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-2-(4-hydroxyphenyl)-ethyl]-succinamic acid,

N-{1-[1-(2-hydroxy-ethyl)-5-(methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-2-phenyl-ethyl}-succinamic acid,

N-{1-[1-(2-hydroxy-ethyl)-5-(methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-3-methylbutyl}-succinamic acid,

({1-cyclopropyl-2-[1- (3-hydroxycarbamoyl-propionylamino)-propyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,

N-{1-[1-benzyl-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]-2-naphthalen-1-yl-ethyl}-succinamic acid,

({1-furan-2-ylmethyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-propyl]-1- H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,

({1-benzyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-propyl]-1H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,

({1-cyclopropyl-2- [1- (3-hydroxycarbamoyl-propionylamino)-3-methyl-butyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,

({1-butyl-2- [1- (3-hydroxycarbamoyl-propionylamino)-3-methyl-butyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,

({1-benzyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-3-methyl-butyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,

; -

- ({1-cyclopropyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-3-methylsulfanyl-propyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-cyclohexylmethyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-3-methylsulfanyl-propyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-benzyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-3-methylsulfanyl-propyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-furan-2-ylmethyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-2-phenyl-ethyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-(4-chloro-benzyl)-2-[1-(3-hydroxycarbamoyl-propionylamino)-2-phenyl-ethyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-cyclopropyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-3-phenyl-propyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-cyclohexylmethyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-3-phenyl-propyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-(2-chloro-benzyl)-2-[1-(3-hydroxycarbamoyl-propionylamino)-2-phenyl-ethyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- {[2-[1-(3-hydroxycarbamoyl-propionylamino)-2-naphthalen-1-yl-ethyl]-1- (2-thiophen-2-yl-ethyl)-1 H-benzoimidazole-5-carbonyl]-amino}-acetic acid methyl ester,
- ({1-butyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-2-naphthalen-1-yl-ethyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-benzyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-2-naphthalen-1-yl-ethyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-butyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-2-phenyl-ethyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({2-[5-amino-1-(3-mercapto-propionylamino)-pentyl]-1-cyclopropyl-1H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({2-[5-amino-1-(3-mercapto-propionylamino)-pentyl]-1-benzyl-1H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,

- ({1-(2-amino-ethyl)-2-[1-(3-mercapto-propionylamino)-2-phenyl-ethyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- N- {5-amino-1- [1-benzyl-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]- pentyl}-succinamic acid,

Docket No.: 64921(45579)

- N- {1- [1- (2-amino-ethyl)-5- (methoxycarbonylmethyl-carbamoyl)-1 H-benzoimidazol-2-yl]- 2-phenyl-ethyl}-succinamic acid,
- ({2-[5-amino-1-(3-hydroxycarbamoyl-propionylamino)-pentyl]-l-cyclopropyl-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({2- [5-amino-1- (3-hydroxycarbamoyl-propionylamino)-pentyl]-1-cyclohexylmethyl-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({2-[5-amino-1-(3-hydroxycarbamoyl-propionylamino)-pentyl]-1-benzyl-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-(2-amino-ethyl)-2-[1-(3-hydroxycarbamoyl-propionylamino)-2-phenyl-ethyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-cyclopropyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-2-(4-hydroxy-phenyl)-ethyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- ({1-cyclohexylmethyl-2-[1-(3-hydroxycarbamoyl-propionylamino)-2-(4-hydroxy-phenyl)-ethyl]-1 H-benzoimidazole-5-carbonyl}-amino)-acetic acid methyl ester,
- {[2-[1-(3-hydroxycarbamoyi-propionylamino)-2-phenyl-ethyl]-l- (2-hydroxy-ethyl)-l H-benzoimidazole-5-carbonyl]-amino}-acetic acid methyl ester; and stereoisomers thereof.
- Claim 21. (currently amended) A compound according to <u>claim 1</u> any of the preceding claims, which in a PDF assay exhibits an IC<sub>50</sub> value of less than 500  $\mu$ M, preferably less than 100  $\mu$ M, more preferably less than 50  $\mu$ M, even more preferably less than 1  $\mu$ M, especially less than 500 nM, particular 300 nM or less.

Claims 22-25. (cancelled)

Page 11

Claim 26. (currently amended) A pharmaceutical composition comprising, as an active ingredient, a compound according to <u>claim 1</u> any of the <u>preceding claims</u> or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

Claim 27. (original) A pharmaceutical composition according to claim 26 comprising a second active substance having antibacterial activity.

Claim 28. (currently amended) A pharmaceutical composition according to claim 26-or 27, wherein the composition is in unit dosage form comprising from about 1 µg to about 1000 mg such as, e. g., from about 10 µg to about 500 µg, from about 0.05 to about 100 µg or from about 0.1 to about 50 mg of the active substance or a pharmaceutically acceptable salt or ester thereof.

Claims 29-30. (cancelled)

Claim 31. (currently amended) A pharmaceutical composition claim according to <u>claim 1 any of claims 26–30 for oral, nasal, transdermal, pulmonal or parenteral administration.</u>

Claim 32. (currently amended) A method for the treatment of <u>an</u> <u>ailmentailments</u>, the method comprising administering to a subject in need thereof an effective amount of a compound according to <u>claim 1 any of claims 1 - 25</u> or a pharmaceutically acceptable salt thereof, or of a composition according to any of claims 26-31.

Docket No.: 64921(45579)

Claim 33. (currently amended) A method according to claim 32, wherein the effective amount of a compound according to any of claims 1-25 or a pharmaceutical acceptable salt or ester thereof is in the range of from about 1 µg to about 1000 µg such as, e. g., from about 10 µg to about 500 µg, from about 0.05 to about 100 µg or from about 0.1 to about 50 µg per day.

Claims 34-38. (cancelled)

Claim 39. (new) A method for the treatment of a patient suffering from or susceptible to a bacterial infection, the method comprising administering to the patient an effective amount of a compound of claim 1.

Claim 40. (new) The method of claim 39 wherein the patient is suffering from a bacterial infection.

Claim 41. (new) The method of claim 39 wherein the patient has been identified and selected for treatment as suffering from a bacterial infection and the compound is administered to the selected patient.

Claim 42. (new) The method of claim 39 wherein the patient is suffering from an infection an organism belonging any of the genera *Staphylococcus*, *Enterococcus*, *Streptococcus*, *Haemophilus*, *Moraxella*, *Escherichia*, *Mycobacterium*, *Mycoplasma*, *Pseudomonas*, *Chlamydia*, *Rickettsia*, *Klebsiella*, *Shigella*, *Salmonella*, *Bordetella*, *Clostridium*, *Helicobacter*, *Campylobacter*, *Legionella* and *Neisseria*.

Claim 43. (new) The method of claim 39 wherein the patient is suffering from an infection associated with an organism belonging to the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecium, Enterococcus faecalis, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Mycobacterium tuberculosis, Mycobacterium ranae, Mycoplasma pneumoniae, Pseudomonas aeruginosa, Chlamydia, Rickettsiae, Klebsiella pneumoniae, Shigella flexneri, Salmonella typhimurium, Bordetella pertussis, Clostridia perfringens, Helicobacterpylori, Campylobacter jejuni, Legionella pneumophila and Neisseria gonorrhoeae.

Docket No.: 64921(45579)